Patient-derived xenografts from circulating cancer stem cells as a preclinical model for personalized pancreatic cancer research

URN to cite this document:: urn:nbn:de:bvb:355-epub-747474
DOI to cite this document:: 10.5283/epub.74747

Wagner, Benedikt J. ; Ettner-Sitter, Andreas ; Ihlo, Nicolas A. ; Behr, Merle

; Koelbl, Sebastian ; Brunner, Stefan M.

; Weber, Florian

; Rau, Bettina M. ; Schlitt, Hans J.

; Brochhausen, Christoph ; Schoenmehl, Rebecca ; Artinger, Annalena ; Schott, Dorothea ; Pizon, Monika ; Pachmann, Katharina ; Aung, Thiha ; Haerteis, Silke

; Hackl, Christina

License: Creative Commons Attribution 4.0
PDF - Published Version
(3MB)

Date of publication of this fulltext: 28 Jan 2025 07:00

Alternative links to fulltext:DOI Publisher

Details

Preview

Export bibliographical data

Abstract

Patient-derived xenografts (PDXs) provide biologically relevant models and potential platforms for the development of treatment strategies for precision medicine in pancreatic cancer. Furthermore, circulating epithelial tumor cells (CETCs/CTCs) are released into the bloodstream by solid tumors and a rare subpopulation—circulating cancer stem cells (cCSCs) – is considered to be responsible for ...